Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Melanoma 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Merkel Cell 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Thymoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Microsatellite Instability 1Mesothelioma 1

Interventions

pembrolizumab 4Nivolumab 3Specimen Handling 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2utomilumab 1tislelizumab 1spartalizumab 1ruxolitinib 1pentetreotide 1niraparib 1montanide ISA 51 1fludarabine phosphate 1entinostat 1avelumab 1Valacyclovir 1Toll-Like Receptor 1 1Spinal Puncture 1Rose Bengal 1Radiosurgery 1LY2940680 1Interleukin-2 1Interleukin-13 1Injections 1Immunologic Techniques 1Fluorodeoxyglucose F18 1Cryosurgery 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × avelumab × Thoracic × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡